Strong Sterling Impacts SmithKline Beecham

22 July 1997

SmithKline Beecham said that currency exchange had a negative impact of12% on its pretax profits in the second quarter of 1997, and the effect on earnings per share was a negative of 13%. However, it stressed the strength of its underlying growth, which seemed to please investors; the firm's share price advanced 49 pence to L12.20 ($20.58) in the initial market reaction to the interim figures.

Second-quarter pretax profits were L356 million ($581 million), which reflected an advance of 4%, or 16% excluding currency. EPS was 8.4 pence, up 1% or 14% excluding currency fluctuations. Trading profit was L377 million, rising 2%, or 14% without the currency impact.

SB experienced a decline in group sales in the quarter of 1% to L1.9 billion, although they rose 8% when stripped of the currency effect. The company said that pharmaceutical products increased 15% in the quarter, while turnover of consumer health care products advanced 14%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight